Daré Bioscience to Present at the 2021 Cantor Virtual Global Healthcare Conference
Daré Bioscience (NASDAQ: DARE) will feature its President and CEO, Sabrina Martucci Johnson, at the Virtual Global Healthcare Conference from September 27 to 30, 2021. Johnson's presentation is scheduled for September 30 at 12:40 p.m. ET. Investors can access a live webcast at this link, with an archived version available until October 15, 2021, on the company's investor website. Daré is known for its commitment to advancing innovative women’s health products, including Ovaprene® and Sildenafil Cream, 3.6%.
- None.
- None.
SAN DIEGO, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will present at the Virtual Global Healthcare Conference being hosted by the Cantor Fitzgerald Healthcare team September 27 – 30, 2021.
| Date: | Thursday, September 30th |
| Time: | 12:40 p.m. ET |
| Presenter: | Sabrina Martucci Johnson, President and Chief Executive Officer |
| Live webcast: | https://wsw.com/webcast/cantor12/dare/2054360 |
An archived webcast of Ms. Johnson’s presentation will be available following the event until October 15, 2021 under “Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.
Daré’s product portfolio includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream,
Daré may announce material information about its finances, product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted on the investor relations page of Daré’s website mentioned above.
Contacts:
Investors on behalf of Daré Bioscience, Inc.:
Lisa Walters-Hoffert, Chief Financial Officer
Daré Bioscience, Inc.
lwalters@darebioscience.com
858.926.7655
OR
Media on behalf of Daré Bioscience, Inc.:
Jake Robison
Canale Communications
jake.robison@canalecomm.com
619.849.5383
Source: Daré Bioscience, Inc.
FAQ
When is Daré Bioscience's presentation at the Global Healthcare Conference?
How can I watch Daré Bioscience's presentation?
When will the archived webcast of Daré's presentation be available?
What is the focus of Daré Bioscience's product development?
What are some products in Daré Bioscience's portfolio?
